hrvatski

Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450

Sažetak u FG se piše na engleskom jeziku. In 1998 mibefradil – an antihypertensive drug, blocker of calcium channel, was withdrawn from the marked after more than 30 clinically significant interactions with other xenobiotics were reported in less than a year on the market. As in most cases enzyme involved was from the superfamily of cytochromes P450. In this paper approach in studying cytochromes P450 and drug inhibitions in vitro is reviewed. Different types of inhibition are described: direct and time dependent inhibition, and metabolism dependent inactivation. These studies were accepted by pharmaceutical industry for the assessment of potential drug- drug interactions in early stages of drug development, and now are being formalized by regulatory bodies in Europe (2013), Japan (2014) and USA to follow.

citokrom P450; inhibicije; interakcije

nije evidentirano